

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



*(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)*

ANNOUNCEMENT

PRELIMINARY FINANCIAL DATA OF SINOPHARM ACCORD FOR THE YEAR OF 2025

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 17 March 2026 (the “**Announcement**”) in relation to the preliminary financial data for the year ended 31 December 2025 (the “**Reporting Period**”) of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data and indicators of Sinopharm Accord for the Reporting Period as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

PRINCIPAL FINANCIAL DATA AND INDICATORS OF SINOPHARM ACCORD

Unit: Ten thousand Yuan

Currency: RMB

	The Reporting Period	Same period of last year	Increase/Decrease
Revenue	7,341,585.84	7,437,849.44	-1.29%
Operating profit	151,282.88	57,347.83	163.80%
Total profit	150,902.03	57,546.94	162.22%
Net profit attributable to shareholders of the listed company	113,592.68	64,249.34	76.80%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	109,569.57	58,117.72	88.53%
Basic earnings per share (Yuan)	2.04	1.15	77.39%
Weighted average ROE	6.26%	3.67%	Increased by 2.59 percentage points
	At the end of the Reporting Period	At the beginning of the Reporting Period	Increase/Decrease
Total assets	4,909,627.10	4,755,586.04	3.24%
Equity attributable to shareholders of the listed company	1,860,996.33	1,766,952.84	5.32%
Share capital (in 0'000 shares)	55,656.51	55,656.51	0.00%
Net assets per share attributable to shareholders of the listed company (Yuan)	33.44	31.75	5.32%

Note: The financial data as at the end of the Reporting Period are filled in according to the consolidated financial statements of Sinopharm Accord.

INFORMATION OF THE OPERATION RESULTS AND FINANCIAL SITUATION

According to the preliminary accounting records, during the Reporting Period, Sinopharm Accord has achieved a revenue of RMB73.416 billion, representing a year-on-year decrease of 1.29%; an operating profit of RMB1.513 billion, representing a year-on-year increase of 163.80%; a total profit of RMB1.509 billion, representing a year-on-year increase of 162.22%; and a net profit attributable to shareholders of the listed company of RMB1.136 billion, representing a year-on-year increase of 76.80%. Accordingly, the basic earnings per share increased by 77.39% year-on-year, and the weighted average ROE increased by 2.59 percentage points year-on-year. The decrease in profit of Sinopharm Accord was mainly due to the year-on-year decrease of RMB686 million in assets impairment provision for goodwill and intangible assets and the decline in rigid expenses and costs including labor costs and rental arising from store adjustments.

With the distribution segment as the operation cornerstone, Sinopharm Accord continued to solidify its core business, actively expanded the market through optimizing resource allocation and product structure, and maintained steady growth in its operation. During the Reporting Period, the distribution segment has achieved a revenue of RMB53.321 billion, representing a year-on-year increase of 0.64%; a net profit of RMB949 million, representing a year-on-year increase of 2.94%.

The retail segment (i.e. “Sinopharm Holding Guoda Drugstore Co., Ltd.” (hereinafter referred to as “**Guoda Drugstore**”)) effectively enhanced the quality of operation by strengthening the commercial procurement system, focusing on its own brands, optimizing the product structure and strategically adjusting the store layout. During the Reporting Period, Guoda Drugstore has achieved a revenue of RMB20.981 billion, representing a year-on-year decrease of 6.16%; a net profit of RMB217 million, representing a year-on-year increase of 80.36%. After excluding the impact of impairment of goodwill and intangible assets, Guoda Drugstore has achieved the net profit of RMB60 million, representing a year-on-year increase of 139.28%.

The year 2026 is not only the first year of the “15th Five-Year” Plan but also a pivotal year for Sinopharm Accord to deepen transformation and move towards high-quality development. In the face of a complex and evolving external environment and profound industry changes, Sinopharm Accord will align with industry trends, maintain strategic focus, continuously focus on high-quality development, center on the major directions of “increasing revenue, reducing costs and enhancing efficiency” for striving to achieve steady progress in business development and steady improvement in operational indicators.

It should be noted by Shareholders and public investors that the principal unaudited financial data and indicators of Sinopharm Accord during the Reporting Period contained in this announcement are only preliminary accounting data, which have not been audited by an accounting firm, and the final data to be disclosed in the annual report of Sinopharm Accord may differ.

By order of the Board
Sinopharm Group Co. Ltd.
Jin Bin
Chairman

Shanghai, the PRC
17 March 2026

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Yang Binghua; the non-executive Directors are Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong and Ms. Li Ying; and the independent non-executive Directors are Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao and Mr. Chen Weiru.